Tenofovir alafenamide versus entecavir for chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This study compares two approved hepatitis B medicines—tenofovir alafenamide and entecavir—to see which works best for people with chronic hepatitis B. It may help improve control of the virus and support better long-term liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be older than 20 years
- Have chronic hepatitis B (a long-term hepatitis B infection)
- Currently need hepatitis B antiviral treatment
- Not have significant liver scarring or failure (Child-Pugh B or C)
- Have kidney function above a certain level (eGFR 15 or higher)
- Be able and willing to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two daily doses of the medicine entecavir to see which one better controls the hepatitis B virus in people with advanced liver scarring (cirrhosis). It aims to find the most effective dose to improve liver health.
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
This study compares two ways of managing hepatitis B while you receive immunotherapy for liver cancer: one group gets a single antiviral drug (TAF), the other gets two antiviral drugs (ETV and TAF). The goal is to see which approach better supports the immunotherapy and improves outcomes.
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.